中文

VERTEX PHARMACEUTICALS INC / MA Revenue Breakdown

Period 2026-03-31 (quarterly) ・ Reported 2026-05-05
ItemAmountY/Y
Revenue$2.99B+7.8%
Gross profit$2.59B
Operating income$1.14B
Net income$1.03B+59.6%
Gross margin86.8%Net margin 34.5%

Revenue Segments

SegmentRevenueShare
TRIKAFTAKAFTRIO$2.35B78.8%
ALYFTREK$0.42B14.2%
Manufactured Product Other$0.14B4.5%
CASGEVY$0.04B1.4%
JOURNAVX$0.03B1.0%
Collaborativeand Royalty$0.00B0.0%

Costs & Expenses

ItemAmount% of revenue
Cost of revenue$0.39B13.2%
SG&A$0.49B16.5%
Tax & other$0.11B3.6%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

VRTVTRSVICIVVSTVMCWRBGWWWABWMTDISWBD

Source: SEC EDGAR · This page shows public filing data only, not investment advice. · Browse all companies